
Gemini Therapeutics
Innovative therapies targeting genetically defined subpopulations in dry AMD and related diseases.
Market cap
$304m
Enterprise value
$217m
Share price
$25.00 GMTX
Authorizing premium user...
Innovative therapies targeting genetically defined subpopulations in dry AMD and related diseases.